168 related articles for article (PubMed ID: 38588626)
81. An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER
Amaral C; Correia-da-Silva G; Almeida CF; Valente MJ; Varela C; Tavares-da-Silva E; Vinggaard AM; Teixeira N; Roleira FMF
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677847
[TBL] [Abstract][Full Text] [Related]
82. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Long X; Fan M; Nephew KP
Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804
[TBL] [Abstract][Full Text] [Related]
83. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
[TBL] [Abstract][Full Text] [Related]
84. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
Brett JO; Spring LM; Bardia A; Wander SA
Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
[TBL] [Abstract][Full Text] [Related]
85. Exploring the Spatial Landscape of the Estrogen Receptor Proximal Proteome With Antibody-Based Proximity Labeling.
Rega C; Kozik Z; Yu L; Tsitsa I; Martin LA; Choudhary J
Mol Cell Proteomics; 2024 Jan; 23(1):100702. PubMed ID: 38122900
[TBL] [Abstract][Full Text] [Related]
86. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
87. Effectiveness of Selective Estrogen Receptor Modulators in Breast Cancer Therapy: An Update.
Das A; Lavanya KJ; Nandini ; Kaur K; Jaitak V
Curr Med Chem; 2023; 30(29):3287-3314. PubMed ID: 36201273
[TBL] [Abstract][Full Text] [Related]
88. Anabolic effect of the traditional Chinese medicine compound tanshinone IIA on myotube hypertrophy is mediated by estrogen receptor.
Zhao P; Soukup ST; Hegevoss J; Ngueu S; Kulling SE; Diel P
Planta Med; 2015 May; 81(7):578-85. PubMed ID: 26018796
[TBL] [Abstract][Full Text] [Related]
89. Estrogen receptors in breast carcinogenesis and endocrine therapy.
Huang B; Warner M; Gustafsson JÅ
Mol Cell Endocrinol; 2015 Dec; 418 Pt 3():240-4. PubMed ID: 25433206
[TBL] [Abstract][Full Text] [Related]
90. Assessing Estrogenic Activity of Classical Estrogen Receptor-Binding Compounds.
Pepermans RA; Prossnitz ER
Methods Mol Biol; 2022; 2418():187-201. PubMed ID: 35119667
[TBL] [Abstract][Full Text] [Related]
91. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Busonero C; Leone S; Bianchi F; Acconcia F
Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
[TBL] [Abstract][Full Text] [Related]
92. Different epigenetic mechanisms of ERα implicated in the fate of fulvestrant-resistant breast cancer.
Tsuboi K; Kaneko Y; Nagatomo T; Fujii R; Hanamura T; Gohno T; Yamaguchi Y; Niwa T; Hayashi SI
J Steroid Biochem Mol Biol; 2017 Mar; 167():115-125. PubMed ID: 27888136
[TBL] [Abstract][Full Text] [Related]
93. Selective oestrogen receptor degraders in breast cancer: a review and perspectives.
Gombos A
Curr Opin Oncol; 2019 Sep; 31(5):424-429. PubMed ID: 31335829
[TBL] [Abstract][Full Text] [Related]
94. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
95. Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.
Ball LJ; Levy N; Zhao X; Griffin C; Tagliaferri M; Cohen I; Ricke WA; Speed TP; Firestone GL; Leitman DC
Mol Cell Endocrinol; 2009 Feb; 299(2):204-11. PubMed ID: 19059307
[TBL] [Abstract][Full Text] [Related]
96. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
97. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies.
Fan W; Chang J; Fu P
Future Med Chem; 2015 Aug; 7(12):1511-9. PubMed ID: 26306654
[TBL] [Abstract][Full Text] [Related]
98. Roles for miRNAs in endocrine resistance in breast cancer.
Muluhngwi P; Klinge CM
Endocr Relat Cancer; 2015 Oct; 22(5):R279-300. PubMed ID: 26346768
[TBL] [Abstract][Full Text] [Related]
99. Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy.
Pan M; Solozobova V; Kuznik NC; Jung N; Gräßle S; Gourain V; Heneka YM; Cramer von Clausbruch CA; Fuhr O; Munuganti RSN; Maddalo D; Blattner C; Neeb A; Sharp A; Cato L; Weiss C; Jeselsohn RM; Orian-Rousseau V; Bräse S; Cato ACB
Cancer Res Commun; 2023 Jul; 3(7):1378-1396. PubMed ID: 37520743
[TBL] [Abstract][Full Text] [Related]
100. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
Long X; Fan M; Bigsby RM; Nephew KP
Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
